HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Abstract
Crohn's disease and ulcerative colitis are chronic, relapsing inflammatory disorders of the GI tract. In both Crohn's disease and ulcerative colitis, leukocytic infiltration of the mucosa is associated with epithelial damage. Recently, monoclonal antibodies directed against cell adhesion molecules (CAMs) involved in leukocyte extravasation have been developed. Natalizumab, the first drug brought to market targeting CAMs, is clinically effective but is associated with serious adverse effects including the uncommon, but often fatal, neurological disease progressive multifocal leukoencephalopathy. Vedolizumab targets a subset of the CAMs blocked by natalizumab and is currently in Phase III trials to study its efficacy and safety in patients with inflammatory bowel disease. Here, we discuss the current treatment options available for patients with Crohn's disease or ulcerative colitis, the history of CAM inhibitors, the current state of development of vedolizumab and its future role in inflammatory bowel disease, if approved by regulatory agencies.
AuthorsLeon P McLean, Terez Shea-Donohue, Raymond K Cross
JournalImmunotherapy (Immunotherapy) Vol. 4 Issue 9 Pg. 883-98 (Sep 2012) ISSN: 1750-7448 [Electronic] England
PMID23046232 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • vedolizumab
Topics
  • Animals
  • Antibodies, Monoclonal, Humanized (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Colitis, Ulcerative (drug therapy)
  • Crohn Disease (drug therapy)
  • Drug and Narcotic Control
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: